Brought to you by 
GSK options Dynavax's TLR inhibitors; collaboration expired
15 Dec 2015
Executive Summary
In a five-year deal, GlaxoSmithKline has received an exclusive worldwide option to four endosomal toll-like receptor (TLR) inhibitors discovered by Dynavax Technologies (modification of innate immune responses) for autoimmune and inflammatory diseases including lupus, rheumatoid arthritis, and psoriasis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK options Dynavax's TLR inhibitors; collaboration expired
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice